EGFR and non-small cell lung carcinoma: Although EGFR-TKIs have brought significant clinical benefits to NSCLC patients, physicians have to face another thorny problem: most patients develop drug resistance after EGFR-TKIs treatment (Mu et al., 2020; Shu et al., 2020; Sun et al., 2020).